Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Yin, Chengliang; Zhang, Junyan; Shen, Ming; Gu, Zhenyang; Li, Yan; Xue, Wanguo; Shi, Jianxin; Huang, Wenrong

doi:10.3389/fonc.2020.01520

Cited by 6 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Another study reported high numbers M 0 macrophages in subjects correlated with better survival. 16 These data are consistent with our data. In another study persons with non-GCB type DLBCL had a decreased proportion of c/d T cells compared to persons with the GCB type in the lymphoma microenvironment.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

A prognostic immune risk score for diffuse large B‐cell lymphoma

Tian

Cai

et al. 2021

Br J Haematol

View full text Add to dashboard Cite

Summary We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10846, n = 305) or validation (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87371 n = 206 and http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117556 n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune‐related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma‐type (germinal centre B cell [GCB] versus non‐GCB), Eastern Cooperative Oncology Group performance status (ECOG‐PS) and rituximab therapy had a C‐statistic of 0·76 compared with C‐statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R‐IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL.

show abstract

Section: Discussionsupporting

confidence: 93%

“…One study reported a high proportion of M 2 macrophages correlated with poorer survival 15 . Another study reported high numbers M 0 macrophages in subjects correlated with better survival 16 . These data are consistent with our data.…”

Section: Discussionsupporting

confidence: 92%

A prognostic immune risk score for diffuse large B‐cell lymphoma

Tian

Cai

et al. 2021

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…M2 macrophages play a dominant role in the long-term IME, which is closely related to the growth, invasion and metastasis of tumor (21,22). Contrary to our previous understanding of M1 macrophages, it plays a protumor role in lymphoma (13).The abundance ratio of M0 macrophages was positively correlated with prognosis (20). The result of CIBERSORT showed that four differential genes were positively correlated with M0 macrophage infiltration, but negatively correlated with M2 macrophage infiltration.…”

Section: Discussioncontrasting

confidence: 61%

“…Both in immunocompetent and immunocompromised NHLs, hub genes are associated with M0, M2 macrophage infiltration. Several articles have reported the role of macrophages in the immune microenvironment in lymphoma ( 13 , 19 , 20 ). M2 macrophages play a dominant role in the long-term IME, which is closely related to the growth, invasion and metastasis of tumor ( 21 , 22 ).…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy

Yao

Xu²,

Li³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEpstein-Barr virus (EBV) is considered a carcinogenic virus, which is associated with high risk for poor prognosis in lymphoma patients, and there has been especially no satisfying and effective treatment for EBV+ lymphoma. We aimed to identify the immunological microenvironment molecular signatures which lead to the poor prognosis of EBV+ lymphoma patients.MethodsDifferential genes were screened with microarray data from the GEO database (GSE38885, GSE34143 and GSE13996). The data of lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) from the TCGA database and GSE4475 were used to identify the prognostic genes. The data of GSE38885, GSE34143, GSE132929, GSE58445 and GSE13996 were used to eluate the immune cell infiltration. Formalin-fixed, paraffin-embedded tissue was collected for Real Time Quantitative PCR from 30 clinical samples, including 15 EBV+ and 15 EBV- lymphoma patients.ResultsFour differential genes between EBV+ and EBV- lymphoma patients were screened out with the significance of the survival and prognosis of lymphoma, including CHIT1, SIGLEC15, PLA2G2D and TMEM163. Using CIBERSORT to evaluate immune cell infiltration, we found the infiltration level of macrophages was significantly different between EBV+ and EBV- groups and was closely related to different genes. Preliminary clinical specimen verification identified that the expression levels of CHIT1 and TMEM163 were different between EBV+ and EBV- groups.ConclusionsOur data suggest that differences in expression levels of CHIT1 and TMEM163 and macrophage infiltration levels may be important drivers of poor prognosis of EBV+ lymphoma patients. These hub genes may provide new insights into the prognosis and therapeutic target for EBV+ lymphoma.

show abstract

“…Thus, it is important to gain further understanding of the underlying metabolic mechanisms of COAD tumorigenesis and progression. Further, it is needed urgently to identify new prognostic-related markers which could become therapeutic potential targets in COAD ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients

Zheng

Wang

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

BackgroundColon adenocarcinoma (COAD) is a highly heterogeneous disease, thus making prognostic predictions uniquely challenging. Metabolic reprogramming is emerging as a novel cancer hallmark that may serve as the basis for more effective prognosis strategies.MethodsThe mRNA expression profiles and relevant clinical information of COAD patients were downloaded from public resources. The least absolute shrinkage and selection operator (LASSO) Cox regression model was exploited to establish a prognostic model, which was performed to gain risk scores for multiple genes in The Cancer Genome Atlas (TCGA) COAD patients and validated in GSE39582 cohort. A forest plot and nomogram were constructed to visualize the data. The clinical nomogram was calibrated using a calibration curve coupled with decision curve analysis (DCA). The association between the model genes' expression and six types of infiltrating immunocytes was evaluated. Apoptosis, cell cycle assays and cell transfection experiments were performed.ResultsUnivariate Cox regression analysis results indicated that ten differentially expressed genes (DEGs) were related with disease-free survival (DFS) (P-value< 0.01). A four-gene signature was developed to classify patients into high- and low-risk groups. And patients with high-risk exhibited obviously lower DFS in the training and validation cohorts (P < 0.05). The risk score was an independent parameter of the multivariate Cox regression analyses of DFS in the training cohort (HR > 1, P-value< 0.001). The same findings for overall survival (OS) were obtained GO enrichment analysis revealed several metabolic pathways with significant DEGs enrichment, G1/S transition of mitotic cell cycle, CD8+ T-cells and B-cells may be significantly associated with COAD in DFS and OS. These findings demonstrate that si-FUT1 inhibited cell migration and facilitated apoptosis in COAD.ConclusionThis research reveals that a novel metabolic gene signature could be used to evaluate the prognosis of COAD, and targeting metabolic pathways may serve as a therapeutic alternative.

show abstract

Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Cited by 6 publications

References 37 publications

A prognostic immune risk score for diffuse large B‐cell lymphoma

A prognostic immune risk score for diffuse large B‐cell lymphoma

Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy

Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients

Contact Info

Product

Resources

About